Vimarsana
Biggest News Aggregation in the World

Page 9 - Solid Tumor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Solid Tumor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Solid Tumor Today - Breaking & Trending Today

United States Squamous-Cell Lung Cancer (SqC-LC) - Vimarsana News

United States Squamous-Cell Lung Cancer (SqC-LC)

Dublin, May 29, 2023 (GLOBE NEWSWIRE) -- The "Squamous-Cell Lung Cancer in the United States, 2022-2042: Cancer Populations USA Report and Data...

United States Non-Squamous Non-Small-Cell Lung Cancer - Vimarsana News

United States Non-Squamous Non-Small-Cell Lung Cancer

Dublin, May 26, 2023 (GLOBE NEWSWIRE) -- The "Non-Squamous Non-Small-Cell Lung Cancer in the United States, 2022-2042: Cancer Populations USA Report and...

InProTher announces €6M seed funding for cancer immunotherapy drug - Vimarsana News

InProTher announces €6M seed funding for cancer immunotherapy drug

Danish early-stage biotech company InProTher has raised €6M seed funding from private investors to advance its lead drug candidate IPT001.

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023 - Vimarsana News

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

NEW YORK, May 17, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data... | May 17, 2023

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023 - Vimarsana News

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

NEW YORK, May 17, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data... | June 12, 2023